Effectiveness and safety profile of fluticasone propionate 0.05% in paediatric dermatoses
DOI:
https://doi.org/10.18203/2320-6012.ijrms20241250Keywords:
Fluticasone propionate, Paediatric dermatoses, Anti-nuclear antibodyAbstract
Background: Topical corticosteroids are effective in the treatment of paediatric dermatoses. However, concerns regarding possible side effects of topical steroids have limited the use of moderate-potency corticosteroids in children. Objective of this study was to evaluate the effectiveness and safety profile of fluticasone propionate 0.05% cream in paediatric dermatoses.
Methods: A total 84 children between 6 months to 12 years of age with moderate to severe dermatoses (< or =30% body surface area) were treated with fluticasone propionate 0.05% cream twice daily for 4 to 6 weeks. Adverse effects of topical steroids were analyzed.
Results: Out of total 84 patients, 46 (54.76%) patients completely cured at 4 weeks and 23 (27.38%) patients at 6 weeks, while remaining 11 (13.10%) patients showed moderate improvement, 4 were lost for follow up after 2 weeks. Only in 2 patients we observed hypopigmentatipon of skin, otherwise in all patients no significant side effect were seen.
Conclusions: Fluticasone propionate 0.05% cream appears to be quite safe for the treatment of moderate to severe dermatoses for up to 4 to 6 weeks in children less than 12 years of age.
Metrics
References
Thappa DM. Common skin problems in children. In J Paediatr. 2002;69:701-06.
Sardana K, Mahajan S, Sarkar R, Mendiratta V, Bhushan P, Koranne RV, et al. The spectrum of skin disease among Indian children. Paediatr Dermatol. 2009;26(1):6-13.
Bonthu I, Purushothaman S, Vukkadala ND. Clinico-etiological study of paediatric dermatoses in tertiary health care hospital in East-coast Andhra Pradesh, India. Int J Res Dermatol. 2020;6(4):456-62.
Jain N, Khandpur. Paediatric dermatoses in India. Indian J Dermatol Venereol Leprol. 2010;76:451-54.
Gardman J, Wolthers OD. Short term growth in children with eczema during treatment with topical mometasone furoate and tacrolimus. Acta Paediatr. 2007;96(8):1233-7.
Friedlander SF, Hebert AA, Allen DB. Fluticasone Pediatrics Safety Study Group. Safety of fluticasone propionate cream 0.05% for the treatment of severe and extensive atopic dermatitis in children as young as 3 months. J Am Acad Dermatol. 2002;46(3):387-93.
Sahasranaman S, Issar M, Hochhaus G. Metabolism of mometasone furoate and biological activity of metabolites. Drug Metab Dispos. 2006;34(2):225-33.
Kanwar AJ, De D. Lichen planus in childhood: Report of 100 cases. Clin Exp Dermatol. 2010;35(3):257-62.
Handa S, Sahoo B. Childhood lichen planus: A study of 87 cases. Int J Dermatol. 2002;41(7):423-7.
Podder I, Agarwall K, Anurag A. Pattern and distribution of pediatric dermatoses and their association with parental socioeconomic status: A single-center experience from India. Ind J Paedia Dermatol. 2022;23(3):214-20.
Lebwohl M. Efficacy and safety of fluticasone propionate ointment, 0.005%, in the treatment of eczema. Cutis. 1996;57(2_Suppl):62-8.
Friedlander SF, Hebert AA, Allen DB. Safety of fluticasone propionate cream 0.05% for the treatment of severe and extensive atopic dermatitis in children as young as 3 months. J Am Acad Dermatol. 2002;46(3):387-93.